Abstracts tagged "Ankylosing spondylitis (AS)"

Abstract Number: 1628 • 2018 ACR/ARHP Annual Meeting
Is Axial Psoriatic Arthritis Distinct from Ankylosing Spondylitis with and without Concomitant Psoriasis?
Joy Feld¹, Justine Y. Ye², Vinod Chandran², Robert D Inman³, Nigil Haroon⁴, Richard J. Cook⁵ and Dafna D Gladman¹, ¹Toronto Psoriatic Arthritis Research Program, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ²Rheumatology, University of Toronto, Toronto Western Hospital, Toronto, ON, Canada, ³Toronto Western Hospital, University of Toronto, Spondylitis Clinic, Toronto, ON, Canada, ⁴Rheumatology, Toronto Western Hospital, Toronto, ON, Canada, Toronto, ON, Canada, ⁵Statistics and Actuarial Science, University of Waterloo, Waterloo, ON, Canada
Background/Purpose: Spondyloarthritis include two major phenotypes: ankylosing spondylitis (AS) and psoriatic arthritis (PsA). 10% of AS patients have concomitant psoriasis, while 25% - 70% of…
Abstract Number: 2431 • 2018 ACR/ARHP Annual Meeting
Birth Outcomes and Disease Activity during Pregnancy in a Prospective Cohort of Women with Psoriatic Arthritis and Ankylosing Spondylitis
Chelsey J F Smith¹, Arthur Kavanaugh² and Christina D Chambers³, ¹Rheumatology, University of California San Diego, La Jolla, CA, ²University of California, San Diego, School of Medicine, La Jolla, CA, ³University of California San Diego Department of Pediatrics, La Jolla, CA
Background/Purpose: The goal of this prospective cohort study is to add to the limited data on birth outcomes in psoriatic arthritis (PsA) and ankylosing spondylitis…
Abstract Number: 450 • 2018 ACR/ARHP Annual Meeting
Injection Site Reaction Associated with Subcutaneous Biologic Agents and Methotrexate. Analysis from the Rhumadata® Clinical Database and Registry
Denis Choquette¹, Louis Bessette², Jacques Brown², Boulos Haraoui¹, Frédéric Massicotte¹, Jean-Pierre Pelletier¹, Jean-Pierre Raynauld¹, Marie-Anaïs Rémillard¹, Diane Sauvageau¹, Angèle Turcotte², Édith Villeneuve¹ and Louis Coupal¹, ¹Rheumatology, Institut de Recherche en Rhumatologie de Montréal (IRRM), Montréal, QC, Canada, ²Rheumatology, Centre de l'Ostéoporose et de Rhumatologie de Québec (CORQ), Québec, QC, Canada
Background/Purpose: Injection Site Reaction (ISRs) are associated with the subcutaneous (SC) route of administration of all biologic agents, and 3% to 15% of patients reports…
Abstract Number: 894 • 2018 ACR/ARHP Annual Meeting
Cancer Risk in Ankylosing Spondylitis in United States Medicare Beneficiaries: Detection of a Chronic Non Steroidal Anti-Inflammatory Drug Use Signature
Sara Alehashemi¹ and Michael Ward², ¹Rheumatology, National Institutes of Health, Bethesda, MD, ²National Institutes of Health, Bethesda, MD, USA, Bethesda, MD
Background/Purpose: Few studies have examined risk of cancer in ankylosing spondylitis (AS) since the end of the radiation therapy era. With greater use of biologics,…
Abstract Number: 1629 • 2018 ACR/ARHP Annual Meeting
Hyperlipoproteinemia (a) in Patients with Spondyloarthritis. Results of the CARMA Study
María Carmen García-Gómez¹, Maria Auxiliadora Martin², Cristina Fernández-Carballido³, Santos Castañeda⁴, Carlos González-Juanatey⁵, Fernando Sánchez-Alonso⁶, María José González-Fernández⁷, Raimon Sanmarti⁸, Alberto Garcia-Vadillo⁹, Benjamin Fernandez Gutierrez¹⁰, Miriam García-Arias¹¹, Javier Manero¹², José Miguel Senabre¹³, Amalia Rueda Cid¹⁴, Sergio Ros Expósito¹⁵, José Manuel Pina Salvador¹⁶, Alba Erra Durán¹⁷, Ingrid Moller¹⁸, Javier Llorca¹⁹ and Miguel Angel González-Gay²⁰, ¹Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ²Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ³Rheumatology Division, Hospital General Universitario de Elda, Elda, Spain, ⁴Rheumatology, Hospital La Princesa. Madrid. Spain, Madrid, Spain, ⁵Division of Cardiology, Hospital Universitario Lucus Augusti, Lugo, Spain, ⁶Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁷Rheumatology, Institut Dexeus, Barcelona, Spain, ⁸Rheumatology Service, Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Hospital Universitario de La Princesa. IIS La Princesa, Madrid, Spain, ¹⁰Rheumatology Department, Hospital Clínico San Carlos, Madrid, Spain, ¹¹Hospital Universitario de la Princesa. Madrid. Spain, Madrid, Spain, ¹²Ophthalmology and Rheumatology, Hospital Miguel Servet. Zaragoza. Spain, Zaragoza, Spain, ¹³Rheumatology, Hospital Marina Baixa, Alicante, Spain, ¹⁴Rheumatology, Hospital General de Valencia, Valencia, Spain, ¹⁵Rheumatology, Hospital de Viladecans, Barcelona, Spain, ¹⁶Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁷Rheumatology, Hospital de Sant Rafael, Barcelona, Spain, ¹⁸Instituto de Poal, Barcelona, Spain, ¹⁹Division of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, Santander, Spain, ²⁰School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: Cardiovascular disease (CVD) is one of the main cause of mortality and morbidity in patients with spondyloarthritis (SpA), partially explained by traditional CV risk…
Abstract Number: 2556 • 2018 ACR/ARHP Annual Meeting
Secukinumab 150mg Provides Sustained Improvements in the Signs and Symptoms of Active Ankylosing Spondylitis with Consistent Safety Profile and High Retention Rate: 4-Year Results from a Phase III Trial
Helena Marzo-Ortega¹, Joachim Sieper², Alan J. Kivitz³, Ricardo Blanco⁴, Martin Cohen⁵, Evie Maria Delicha⁶, Susanne Rohrer⁶ and Hanno Richards⁶, ¹NIHR LBRC, LTHT and LIRMM, University of Leeds, Leeds, United Kingdom, ²University Clinic Benjamin Franklin, Berlin, Germany, ³Altoona Center for Clinical Research, Duncansville, PA, ⁴Hospital Universitario Marqués de Valdecilla, Santander, Spain, ⁵McGill University, Montreal, QC, Canada, ⁶Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Secukinumab, a fully human monoclonal IgG1 antibody that neutralizes IL-17A, has shown significant and sustained improvement in the signs and symptoms of active ankylosing…
Abstract Number: 3L • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Low Radiographic Progression and Sustained Efficacy through 4 Years in Patients with Active Ankylosing Spondylitis
Jürgen Braun¹, Xenofon Baraliakos¹, Atul A. Deodhar², Denis Poddubnyy³, Paul Emery⁴, Evie Maria Delicha⁵, Zsolt Talloczy⁶ and Brian Porter⁶, ¹Rheumazentrum Ruhrgebiet, Herne, and Ruhr University Bochum, Herne, Germany, ²Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ³Department of Rheumatology, Charité Universitätsmedizin Berlin, Berlin, Germany, ⁴Leeds Musculoskeletal Biomedical Research Unit/Institute Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom, ⁵Novartis Pharma AG, Basel, Switzerland, ⁶Novartis Pharmaceuticals Corporation, East Hanover, NJ

Background/Purpose: Secukinumab, a fully human anti–interleukin-17A monoclonal antibody, reported improved signs and symptoms of ankylosing spondylitis (AS) in the MEASURE 1 trial.1 Here, we report…
Abstract Number: 337 • 2017 ACR/ARHP Annual Meeting
Patient-Reported Flares Were Correctly Predicted By an Algorithm Using Machine-Learning Statistics on Activity Tracker Data on Steps, in a Longitudinal 3-Month Study of 170 Patients with Rheumatoid Arthritis (RA) or Axial Spondyloarthritis (axSpA)
Laure Gossec¹, Frédéric Guyard², Didier Leroy³, Thomas Lafargue², Michel Seiler³, Charlotte Jacquemin¹, Anna Molto⁴, Jeremie Sellam⁵, Violaine Foltz¹, Frédérique Gandjbakhch¹, Christophe Hudry⁶, Stéphane Mitrovic¹, Bruno Fautrel¹ and Herve Servy⁷, ¹UPMC University Paris 06, Pitié-Salpétrière Hospital, Paris, France, ²IMT, Orange, Nice, France, ³Healthcare, Orange, Paris, France, ⁴Hôpital Cochin, Department of Rheumatology, Paris Descartes University, Paris, France, ⁵Rheumatology, Saint-Antoine Hospital, Paris, France, ⁶AP-HP Hôpital Cochin, Paris, France, ⁷e-health services, Sanoia, Gemenos, France
Background/Purpose: The natural history of RA and axSpA comprises periods of low disease activity and flares. However, there are few data linking patient-reported flares to…
Abstract Number: 1523 • 2017 ACR/ARHP Annual Meeting
Secukinumab Demonstrates Rapid and Sustained Efficacy in Ankylosing Spondylitis Patients with Normal or Elevated Baseline CRP Levels: Pooled Analysis of Two Phase 3 Studies
Jürgen Braun¹, Joachim Sieper², Robert B.M. Landewé³, Xenofon Baraliakos¹, Corinne Miceli-Richard⁴, Ruvie Martin⁵, Brian Porter⁵, Kunal Gandhi⁵ and Désirée van der Heijde⁶, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, ²Charité University Medicine Berlin, Berlin, Germany, ³University of Amsterdam and Atrium Medical Center, Amsterdam, Netherlands, ⁴Department of Rheumatology, Hôpital Bicêtre, Paris, France, ⁵Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁶Leiden University Medical Center, Leiden, Netherlands
Background/Purpose: Inhibition of IL-17A with secukinumab is an approved therapy for patients (pts) with AS.1 It has been previously reported that response rates with TNFα…
Abstract Number: 1552 • 2017 ACR/ARHP Annual Meeting
Persistency of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There are limited data regarding persistency of TNF inhibitor (TNFi) therapies in patients with ankylosing spondylitis (AS) treated in real-world clinical practice. The objective…
Abstract Number: 2517 • 2017 ACR/ARHP Annual Meeting
The Usefulness of Trabecular Bone Score in Assessing the Bone Strength and Fracture Risk of Patients with Ankylosing Spondylitis
Seoung Wan Nam¹, Yoon-Kyoung Sung², Dam Kim², Soo-Kyung Cho³, Yoonah Song⁴, Yun Young Choi⁵ and Tae-Hwan Kim², ¹Department of Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ²Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ³Rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Department of Radiology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁵Department of Nuclear Medicine, Hanyang University Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Ankylosing spondylitis (AS) is a disease characterized by spinal osteoproliferation (syndesmophytosis) and the general trabecular bone loss with increased fracture risk. Syndesmophyts in spine…
Abstract Number: 577 • 2017 ACR/ARHP Annual Meeting
The Value of C-Reactive Protein As a Predictor of Radiographic Spinal Progression Is Strongly Dependent on β-Fibrinogen and Factor XIII a-Subunit Genotypes in Patients with Axial Spondyloarthritis
Denis Poddubnyy^1,2, Christian Schwedler², Hildrun Haibel², Martin Rudwaleit^2,3, Joachim Sieper² and Berthold Hoppe⁴, ¹German Rheumatism Research Centre, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Berlin, Germany, ³Klinikum Bielefeld Rosenhöhe, Bielefeld, Germany, ⁴Unfallkrankenhaus Berlin, Berlin, Germany
Background/Purpose: It has been shown in the past that inflammatory activity (i.e., elevated C-reactive protein) predicts radiographic spinal progression in patients with axial spondyloarthritis (axSpA).…
Abstract Number: 1526 • 2017 ACR/ARHP Annual Meeting
Shift Analysis of Spinal Radiographic Progression after 2 Years of Secukinumab in Ankylosing Spondylitis – Detailed Results from a Phase 3 Trial
Xenofon Baraliakos¹, Jürgen Braun¹, Albert Widmer², Ayan Das Gupta³, Aimee Readie⁴, Brian Porter⁴ and Corine Gaillez², ¹Rheumazentrum Ruhrgebiet, Herne, Germany, ²Novartis Pharma AG, Basel, Switzerland, ³Novartis Healthcare Pvt. Ltd, Hyderabad, India, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ
Background/Purpose: An overall low rate of spinal radiographic progression with the modified Stoke Ankylosing Spondylitis Spinal Score (mSASSS) was reported with secukinumab (SEC), a fully…
Abstract Number: 1553 • 2017 ACR/ARHP Annual Meeting
Discontinuation of Tumor Necrosis Factor Inhibitor Therapy in US Patients with Ankylosing Spondylitis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis (PsA/SpA) Registry
Philip J Mease¹, Désirée van der Heijde², Chitra Karki³, Mei Liu³, Yujin Park⁴ and Jeffrey D. Greenberg⁵, ¹Swedish Medical Center and University of Washington, Seattle, WA, ²Leiden University Medical Center, Leiden, Netherlands, ³Corrona, LLC, Southborough, MA, ⁴Novartis Pharmaceuticals Corporation, East Hanover, NJ, ⁵New York University School of Medicine, New York, NY
Background/Purpose: There is a need to better characterize patients with ankylosing spondylitis (AS) who discontinue vs continue TNF inhibitor (TNFi) therapies in real-world clinical settings.…
Abstract Number: 2519 • 2017 ACR/ARHP Annual Meeting
Characteristics of Eye Diseases in Patients with Ankylosing Spondylitis in Korea: A Single-Center Survey
Seunghun Lee¹, Bon San Koo², Ji Hui Shin³ and Tae-Hwan Kim⁴, ¹Department of Radiology, Hanyang University Hospital, Seoul, Korea, Republic of (South), ²rheumatology, Inje University College of Medicine, seoul, Korea, Republic of (South), ³rheumatology, Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South), ⁴Hanyang University Hospital for Rheumatic Diseases, Seoul, Korea, Republic of (South)
Background/Purpose: Uveitis is the most common extra-articular manifestation occurring in patients with ankylosing spondylitis (AS). The purpose of this study is to evaluate the characteristics…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].